Valneva, Pfizer announce positive phase 2 paediatric data for Lyme disease vaccine candidate

Valneva SE, a specialty vaccine company, and Pfizer Inc. reported positive phase 2 paediatric data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed with inclusion of paediatric participants in their planned phase 3 trial. The trial will evaluate VLA15 in adults and paediatric subjects 5 years of age and above and is expected to be initiated in the third quarter of 2022, subject to regulatory approval. The phase 2 trial, VLA15-221, is the first clinical study with VLA15 which enrolled a paediatric population (5-17 years old). It compared the immunogenicity and safety of VLA15 after administration of two (at months 0 and 6) or three (at months 0, 2 and 6) primary series doses in groups aged 5-11, 12-17 and 18-65 years. In paediatric participants (5-17 years old) who received VLA15 in either the two-dose schedule (N=93) or three-dose schedule (N=97), VLA15 was found to be more immunogenic than in adults with both vaccination schedules tested. These data build on the strong immunogenicity profile already reported for adult participants (18-65 years old) in February 2022. Like in adults, the immunogenicity and safety data support a three-dose primary vaccination schedule in paediatric participants in the phase 3 study. The safety and tolerability profile observed in the 5- to 17-year age group was similar to the previously reported profile in adult participants. No vaccine-related serious adverse events (SAEs) were observed. Valneva and Pfizer plan to submit these data for publication and presentation at a future scientific congress. Juan Carlos Jaramillo M.D., chief medical officer of Valneva, said,

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!